Novo Nordisk Finds Medicare Patients Prefer GLP-1 Pill Over Shot for Weight Loss
Novo Nordisk A/S said its market research shows twice as many US Medicare recipients would rather take a…
Orsted Jumps After Ruling Revives Trump-Halted Wind Project
Orsted A/S shares surged after a US judge ruled work can resume on a wind farm off the…
Maersk CEO Sees Solid Container Demand Sustained in Second Half
The head of A.P. Moller-Maersk A/S, the world’s No. 2 container carrier, said he expects global demand for…
Orsted (ORSTED DC) Mulls Over $1 Billion Sale of US Renewable Assets
Orsted A/S is exploring a sale of its onshore renewables assets in the US, people with knowledge of…
Danske Bank Raises Profitability Target, Unveils Payout
Danske Bank A/S, the largest lender in Denmark, lifted its profitability target after saying it’s on track to…
Vestas Halts Poland Blade Factory as European Demand Wanes
Vestas Wind Systems A/S halted development of a major factory in Poland to produce blades for offshore wind…
Novo Nordisk’s Wegovy Pill Draws 10,000-Person UK Waiting List at Chemist4U
Chemist4U already has a waiting list of more than 10,000 customers interested in Novo Nordisk A/S’s Wegovy pill,…
Novo Nordisk CEO Looks Beyond Weight Loss to Longevity, Aesthetics
Novo Nordisk A/S Chief Executive Officer Mike Doustdar says the company’s blockbuster obesity drugs could ultimately pull it…
Pimco, L&G Sued Over €1.2 Billion Brussels Skyscraper Valuation
Pimco and Legal & General Group Plc have been accused of placing “undue pressure” on property valuers in…
Novo Transfers Parkinson’s Therapy to Zuckerberg-Backed Cellular Intelligence
Novo Nordisk A/S agreed to hand over an experimental therapy for Parkinson’s disease to a Mark Zuckerberg-backed AI…
Novo Obesity Shot Wegovy Helped Alcoholics Drink Less in Study
Novo Nordisk A/S’s obesity shot Wegovy helped people with alcoholism reduce their drinking, in the first controlled study…
Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name
Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid…